Humanized IgG1 monoclonal antibody targeting CD117 (c-KIT) on hematopoietic stem and progenitor cells; blocks SCF-c-KIT signaling to deplete CD117+ cells. Administered IV on Day 1 of each 8-week cycle for up to 4 cycles.
Humanized IgG1 monoclonal antibody targeting CD117 (c-KIT) on hematopoietic stem and progenitor cells; blocks stem cell factor (SCF)–c-KIT signaling to suppress survival/maintenance and deplete CD117+ cells (including malignant clones), with depletion aided by Fc-mediated effector functions such as ADCC/phagocytosis.
The anti-CD117 IgG1 binds c-KIT on CD117+ cells, blocks SCF–c-KIT survival signaling, and engages Fcγ receptor–bearing immune cells to mediate ADCC and antibody-dependent phagocytosis, depleting/killing CD117+ cells.
Chimeric anti‑CD20 IgG1 monoclonal antibody that induces B‑cell depletion via ADCC, CDC, and apoptosis.
Chimeric anti‑CD20 IgG1 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and induction of apoptosis.
Binds CD20 on B cells and induces Fc-mediated ADCC by NK/macrophages, complement-dependent cytotoxicity (MAC formation), and can trigger apoptosis via CD20 crosslinking.
Glycoengineered type II anti‑CD20 IgG1 monoclonal antibody with enhanced ADCC and direct cell death.
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells; its afucosylated Fc increases affinity for Fc-gamma RIIIa, enhancing ADCC (and ADCP), and it induces direct, caspase-independent cell death, leading to B-cell depletion.
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages Fc-gamma RIIIa on effector cells to drive potent ADCC/ADCP and it also induces direct, caspase-independent cell death of CD20+ cells (with limited CDC).
Defucosylated humanized anti-CCR4 monoclonal antibody (Poteligeo) that binds CCR4 on malignant T cells and Tregs, blocks chemokine signaling/trafficking, and enhances Fc-mediated ADCC to deplete CCR4+ cells.
Defucosylated humanized anti-CCR4 monoclonal antibody (mogamulizumab/Poteligeo) that binds CCR4 on malignant T cells and Tregs, blocks CCR4 chemokine signaling and trafficking, and enhances Fc-mediated ADCC to deplete CCR4-positive cells.
Mogamulizumab binds CCR4 on target cells and, via its defucosylated Fc, strongly engages Fcγ receptors on NK cells to trigger ADCC (and phagocytes for ADCP), depleting CCR4+ cells.
Fc-competent anti-TIGIT monoclonal antibody (GSK4428859A/EOS-448) that blocks TIGIT interactions with CD155/CD112 to enhance T- and NK-cell activity and may deplete TIGIT-high Tregs via ADCC.
Fc-competent anti-TIGIT IgG1 monoclonal antibody that blocks TIGIT interactions with CD155/CD112, restoring CD226 co-stimulation to activate T and NK cells; its Fc domain can mediate ADCC to deplete TIGIT-high regulatory T cells, enhancing anti-tumor immunity.
IgG1 Fc engages Fcγ receptors to mediate ADCC/ADCP against TIGIT-high cells (e.g., Tregs) bound by the antibody, leading to their depletion.